ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation

NASDAQ:ASTH • US03763A2078

Current stock price

24.23 USD
+0.05 (+0.21%)
At close:
24.23 USD
0 (0%)
After Hours:

This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ASTH Profitability Analysis

1.1 Basic Checks

  • In the past year ASTH was profitable.
  • In the past year ASTH had a positive cash flow from operations.
  • Each year in the past 5 years ASTH has been profitable.
  • ASTH had a positive operating cash flow in each of the past 5 years.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

1.2 Ratios

  • ASTH has a Return On Assets (1.01%) which is in line with its industry peers.
  • ASTH has a Return On Equity (2.89%) which is in line with its industry peers.
  • ASTH has a Return On Invested Capital of 3.75%. This is comparable to the rest of the industry: ASTH outperforms 47.52% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 8.86%.
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROIC 3.75%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • ASTH has a Profit Margin (0.71%) which is in line with its industry peers.
  • ASTH's Profit Margin has declined in the last couple of years.
  • ASTH has a Operating Margin of 3.08%. This is comparable to the rest of the industry: ASTH outperforms 54.46% of its industry peers.
  • ASTH's Operating Margin has declined in the last couple of years.
  • ASTH has a Gross Margin of 10.73%. This is in the lower half of the industry: ASTH underperforms 73.27% of its industry peers.
  • ASTH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASTH Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
  • The number of shares outstanding for ASTH has been increased compared to 1 year ago.
  • Compared to 5 years ago, ASTH has more shares outstanding
  • The debt/assets ratio for ASTH is higher compared to a year ago.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.41. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.41, ASTH perfoms like the industry average, outperforming 58.42% of the companies in the same industry.
  • The Debt to FCF ratio of ASTH is 9.94, which is on the high side as it means it would take ASTH, 9.94 years of fcf income to pay off all of its debts.
  • ASTH has a Debt to FCF ratio (9.94) which is comparable to the rest of the industry.
  • ASTH has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of ASTH (1.27) is worse than 64.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Altman-Z 2.41
ROIC/WACC0.45
WACC8.39%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • ASTH has a Current Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • ASTH has a Current ratio (1.40) which is in line with its industry peers.
  • ASTH has a Quick Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • ASTH has a Quick ratio (1.40) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ASTH Growth Analysis

3.1 Past

  • ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
  • ASTH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.74% yearly.
  • ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.39%.
  • ASTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.87% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%

3.2 Future

  • The Earnings Per Share is expected to grow by 54.34% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ASTH will show a quite strong growth in Revenue. The Revenue will grow by 9.59% on average per year.
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. ASTH Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 52.67, the valuation of ASTH can be described as expensive.
  • ASTH's Price/Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 25.23, ASTH is valued quite expensively.
  • The Price/Forward Earnings ratio is 19.20, which indicates a rather expensive current valuation of ASTH.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ASTH.
  • ASTH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.42, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 52.67
Fwd PE 19.2
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ASTH is on the same level as its industry peers.
  • 78.22% of the companies in the same industry are more expensive than ASTH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.47
EV/EBITDA 12.56
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ASTH's earnings are expected to grow with 87.86% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y103.85%
EPS Next 3Y87.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASTH Dividend Analysis

5.1 Amount

  • No dividends for ASTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTH Fundamentals: All Metrics, Ratios and Statistics

ASTRANA HEALTH INC

NASDAQ:ASTH (3/20/2026, 8:00:01 PM)

After market: 24.23 0 (0%)

24.23

+0.05 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners59.72%
Inst Owner ChangeN/A
Ins Owners9.87%
Ins Owner Change0.91%
Market Cap1.20B
Revenue(TTM)3.18B
Net Income(TTM)22.49M
Analysts84.71
Price Target36.38 (50.14%)
Short Float %7.49%
Short Ratio5.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP35.06%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.4%
Min EPS beat(2)-97.78%
Max EPS beat(2)10.99%
EPS beat(4)1
Avg EPS beat(4)-44.97%
Min EPS beat(4)-97.78%
Max EPS beat(4)10.99%
EPS beat(8)4
Avg EPS beat(8)-50.25%
EPS beat(12)7
Avg EPS beat(12)-23.47%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.15%
Revenue beat(4)2
Avg Revenue beat(4)-1.11%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)0.57%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.78%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-11.39%
EPS NQ rev (1m)29.91%
EPS NQ rev (3m)29.91%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-8.28%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 52.67
Fwd PE 19.2
P/S 0.38
P/FCF 11.47
P/OCF 10.46
P/B 1.54
P/tB N/A
EV/EBITDA 12.56
EPS(TTM)0.46
EY1.9%
EPS(NY)1.26
Fwd EY5.21%
FCF(TTM)2.11
FCFY8.72%
OCF(TTM)2.32
OCFY9.56%
SpS64.32
BVpS15.75
TBVpS-7.22
PEG (NY)0.3
PEG (5Y)N/A
Graham Number12.77
Profitability
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROCE 6.12%
ROIC 3.75%
ROICexc 5.12%
ROICexgc 160.26%
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
FCFM 3.28%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ROICexc(3y)8.45%
ROICexc(5y)10.18%
ROICexgc(3y)90.21%
ROICexgc(5y)71.8%
ROCE(3y)9%
ROCE(5y)10.61%
ROICexgc growth 3Y64.68%
ROICexgc growth 5Y30.22%
ROICexc growth 3Y-25.1%
ROICexc growth 5Y-14.45%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
F-Score4
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Debt/EBITDA 6.89
Cap/Depr 22.09%
Cap/Sales 0.32%
Interest Coverage 2.14
Cash Conversion 79.65%
Profit Quality 464.67%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.41
F-Score4
WACC8.39%
ROIC/WACC0.45
Cap/Depr(3y)70.53%
Cap/Depr(5y)90.42%
Cap/Sales(3y)0.92%
Cap/Sales(5y)1.45%
Profit Quality(3y)210.81%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%
EBIT growth 1Y9.82%
EBIT growth 3Y-2%
EBIT growth 5Y4.04%
EBIT Next Year220.54%
EBIT Next 3Y60.15%
EBIT Next 5Y39.29%
FCF growth 1Y136.58%
FCF growth 3Y20.86%
FCF growth 5Y18.35%
OCF growth 1Y119.54%
OCF growth 3Y11.74%
OCF growth 5Y19.94%

ASTRANA HEALTH INC / ASTH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 52.67 and the Price/Book (PB) ratio is 1.54.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.